5-hydroxymethylcytosine has been researched along with Central Nervous System Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizgolshani, N; Chen, Y; Christensen, BC; Levy, JJ; Nguyen, LN; Perreard, L; Petersen, CL; Salas, LA | 1 |
| Chen, CD; Fu, X; Li, J; Li, Q; Li, X; Lin, W; Liu, Y; Wan, Y; Wang, Y; Wang, Z; Xu, Y; Yan, Q; Ye, J; Zhang, F; Zhang, J; Zhang, L; Zhang, M; Zhang, X; Zhang, Z | 1 |
2 other study(ies) available for 5-hydroxymethylcytosine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
Topics: 5-Methylcytosine; Adolescent; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Gene Expression Regulation; Humans; Male; Neoplasm Staging; Pediatrics | 2021 |
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.
Topics: 5-Methylcytosine; Adolescent; Adult; Aged; Antibodies; Astrocytoma; Biomarkers, Tumor; Brain; Central Nervous System Neoplasms; Cytosine; Female; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Ki-67 Antigen; Male; Middle Aged; Mutation; Neoplasm Grading; Prognosis; Spinal Cord; Survival Analysis | 2016 |